Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0076 | 0.1126 | 0.1126 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1126 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0076 | 0.1126 | 0.1126 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1126 | 0.5 |
Plasmodium falciparum | choline kinase | 0.0205 | 1 | 0.5 |
Plasmodium vivax | choline kinase, putative | 0.0205 | 1 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1126 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1126 | 0.5 |
Echinococcus multilocularis | choline:ethanolamine kinase | 0.0205 | 1 | 1 |
Loa Loa (eye worm) | choline/ethanolamine kinase | 0.0205 | 1 | 1 |
Toxoplasma gondii | phosphotransferase enzyme family protein | 0.0205 | 1 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0076 | 0.1126 | 0.1126 |
Brugia malayi | RNA binding protein | 0.0076 | 0.1126 | 0.1126 |
Loa Loa (eye worm) | RNA binding protein | 0.0076 | 0.1126 | 0.1126 |
Echinococcus granulosus | choline:ethanolamine kinase | 0.0205 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0076 | 0.1126 | 0.5 |
Brugia malayi | TAR-binding protein | 0.0076 | 0.1126 | 0.1126 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 4.6535 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 7.3753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.